| Methods |
2‐to 4‐week single‐blind placebo washout; inclusion criteria= supine DBP 95‐114 mm Hg after washout; 12‐week double‐blind treatment |
| Participants |
Ramipril 1.25 mg: n=44(18 males,26 females); mean age=52.3 years; baseline SBP=159(15) mm Hg, DBP=99.9(3.7) mm Hg;
Ramipril 2.5 mg: n=43(27 males,16 females); mean age=49.4 years; baseline supine DBP=99.8(3.7) mm Hg;
Ramipril 5 mg: n=43(23 males,20 females); mean age=53.4 years; baseline supine DBP=100.7(5.1) mm Hg;
Ramipril 10 mg: 44(29 males,15 females); mean age=52.1 years; baseline supine DBP=101.2(4.4) mm Hg;
Placebo: n=42(22 males,20 females); mean age=51.3 years; baseline supine DBP=99.3(3.6) mm Hg |
| Interventions |
Ramipril 1.25 mg once daily;
Ramipril 2.5 mg once daily;
Ramipril 5 mg once daily;
Ramipril 10 mg once daily;
Placebo;
administered in the morning |
| Outcomes |
Mean change from baseline in trough standing SBP/DBP using mercury sphygmomanometer;
Mean change from baseline in trough supine SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SD of change reported, endpoint BP and SD not reported; BP data from Table 3, p. 13, SD data from Figures II and III, p. 12; Jadad score=3; funding source= not reported |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
